Home Other Building Blocks 2(3H)-BENZOXAZOLONE, 7-(4-METHYL-1-PIPERAZINYL)-, MONOHYDROCHLORIDE

2(3H)-BENZOXAZOLONE, 7-(4-METHYL-1-PIPERAZINYL)-, MONOHYDROCHLORIDE

CAS No.:
269718-83-4
Catalog Number:
AG00BF6E
Molecular Formula:
Molecular Weight:
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
5mg
98%
1 week
United States
$640
- +
10mg
98%
1 week
United States
$890
- +
50mg
98%
1 week
United States
$2557
- +
100mg
98%
1 week
United States
$3557
- +
Product Description
Catalog Number:
AG00BF6E
Chemical Name:
2(3H)-BENZOXAZOLONE, 7-(4-METHYL-1-PIPERAZINYL)-, MONOHYDROCHLORIDE
CAS Number:
269718-83-4
MDL Number:
MFCD09833663
IUPAC Name:
7-(4-methylpiperazin-1-yl)-3H-1,3-benzoxazol-2-one;hydrochloride
InChI:
InChI=1S/C12H15N3O2.ClH/c1-14-5-7-15(8-6-14)10-4-2-3-9-11(10)17-12(16)13-9;/h2-4H,5-8H2,1H3,(H,13,16);1H
InChI Key:
NQRIKTDKFHAOKC-UHFFFAOYSA-N
UNII:
U40903X6V8
Properties
Complexity:
302  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
2  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
269.093g/mol
Formal Charge:
0
Heavy Atom Count:
18  
Hydrogen Bond Acceptor Count:
4  
Hydrogen Bond Donor Count:
2  
Isotope Atom Count:
0
Molecular Weight:
269.729g/mol
Monoisotopic Mass:
269.093g/mol
Rotatable Bond Count:
1  
Topological Polar Surface Area:
44.8A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
Literature
Title Journal
Pardoprunox as adjunct therapy to levodopa in patients with Parkinson's disease experiencing motor fluctuations: results of a double-blind, randomized, placebo-controlled, trial. Parkinsonism & related disorders 20120501
Temporal stability of the Unified Dyskinesia Rating Scale. Movement disorders : official journal of the Movement Disorder Society 20111201
In vivo effects of pardoprunox (SLV308), a partial D₂/D₃ receptor and 5-HT1A receptor agonist, on rat dopamine and serotonin neuronal activity. Synapse (New York, N.Y.) 20111001
Identification of N-propylnoraporphin-11-yl 5-(1,2-dithiolan-3-yl)pentanoate as a new anti-Parkinson's agent possessing a dopamine D2 and serotonin 5-HT1A dual-agonist profile. Journal of medicinal chemistry 20110714
Pardoprunox in early Parkinson's disease: results from 2 large, randomized double-blind trials. Movement disorders : official journal of the Movement Disorder Society 20110701
The partial dopamine agonist pardoprunox (SLV308) administered in combination with l-dopa improves efficacy and decreases dyskinesia in MPTP treated common marmosets. Experimental neurology 20101201
Pardoprunox reverses motor deficits but induces only mild dyskinesia in MPTP-treated common marmosets. Movement disorders : official journal of the Movement Disorder Society 20101015
An in vivo pharmacological evaluation of pardoprunox (SLV308)--a novel combined dopamine D(2)/D(3) receptor partial agonist and 5-HT(1A) receptor agonist with efficacy in experimental models of Parkinson's disease. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 20100801
Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society 20100430
Safety and tolerability of pardoprunox, a new partial dopamine agonist, in a randomized, controlled study of patients with advanced Parkinson's disease. European neurology 20090101
In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist. Synapse (New York, N.Y.) 20061215
SLV-308. Solvay. Current opinion in investigational drugs (London, England : 2000) 20030701
Properties